London, United Kingdom
Fortuna Fix, founded in 2016 and headquartered in the United Kingdom, is poised to revolutionize the field of regenerative medicine. With the slogan "Reprogram and regenerate. A revolution in medicine," the company is focused on neuronal repair and regeneration, offering potential cures for conditions that current therapeutic modalities cannot adequately address.
At the core of Fortuna Fix's innovation are their drNPC™ (autologous neural precursor cells produced by direct reprogramming), regenerative implants Regeneration Matrix™ (RMx™), and their patent-pending fully Automated Manufacturing process, which promises rapid scaling of drNPC™ production. Their ethical approach to regenerative medicine is particularly noteworthy, aiming to restore full functionality to patients affected by neurotrauma and neurodegeneration.
The company received a $25.00M Series B investment from notable investors Amgen Ventures and Amgenbd in November 2017. This capital infusion underscores substantial investor confidence in Fortuna Fix's groundbreaking technology.
